DLA Piper Advises Pfizer Ventures on Strategic Investment in Artios Pharma

"DLA Piper advised Pfizer Ventures, the venture capital arm of Pfizer Inc., on its strategic investment in Artios Pharma Limited as part of Artios’ oversubscribed USD 115 million Series D financing. The proceeds will advance Artios’ clinical pipeline, including lead programme alnodesertib, which has received U.S. FDA Fast Track Designation."

DLA Piper advised Pfizer Ventures, the venture capital arm of Pfizer Inc., in connection with Pfizer Ventures’ strategic investment in Artios Pharma Limited. The transaction formed part of Artios’ oversubscribed USD 115 million Series D financing. Artios is a biopharmaceutical company developing cancer medicines that selectively target vulnerabilities in the way tumor cells repair DNA damage. The Series D proceeds will be used to advance Artios’ clinical pipeline, including its lead programme, alnodesertib, which has recently been granted U.S. FDA Fast Track Designation. Pfizer Ventures invests globally in innovative companies at all stages of development, with a strong focus on early-stage life-science opportunities that align with Pfizer's strategic areas. In addition to providing capital, Pfizer Ventures partners with its portfolio companies by offering strategic guidance and access to Pfizer's scientific and development expertise. DLA Piper represented Pfizer Ventures with a team composed by: Corporate partner Luca Gori, Senior Associate Alex Potop and Associate Annisa Chan.

DLA Piper Advises Pfizer Ventures on Strategic Investment in Artios Pharma

Read the full story

Cookie Preferences

Strictly Necessary

Analytics & Statistics

Marketing & Ads